COGNIZANCE ANALYSIS OF MAGICAL REMEDY COMBINATION OF NETUPITANT AND PALANOSETRON(NEPA) FOR CHEMOTHERAPY INDUCED NAUSEA AND VOMITING THERAPY

  • Srinivas Pasula Department of Pharmacy, Amdapur X Road, Yenkapally, Moinabad, Ranga Reddy, Hyderabad, Telangana 500075.
    sreenu.pasula@gmail.com
  • Greeshma Kothakoti Department of Pharmacy, Amdapur X Road, Yenkapally, Moinabad, Ranga Reddy, Hyderabad, Telangana 500075.
  • Arunima Alluri Department of Pharmacy, Amdapur X Road, Yenkapally, Moinabad, Ranga Reddy, Hyderabad, Telangana 500075.
  • Geetha Rekulapally Department of Pharmacy, Amdapur X Road, Yenkapally, Moinabad, Ranga Reddy, Hyderabad, Telangana 500075.
  • Beda Durga Prasad Department of Pharmacy, Amdapur X Road, Yenkapally, Moinabad, Ranga Reddy, Hyderabad, Telangana 500075.
  • A. Srinivasa Rao Department of Pharmacy, Amdapur X Road, Yenkapally, Moinabad, Ranga Reddy, Hyderabad, Telangana 500075.

Abstract

Objective: chemotherapy induced nausea and vomiting (CINV) keeps on being one of the major dreaded symptoms of chemotherapy. Insufficiently controlled CINV can have a significant negative effect on personal satisfaction and can at times compromise adherence to treatment.Various antiemetic specialists are right now accessible for the prophylaxis and treatment of CINV howeverWith the right utilization of antiemetic specialists, CINV can be forestalled, as it were, be that as it may, adherence to rules is disappointingly low. Therefor accomplishing of CINV composition of Netupitant and Palanosetron are naval huge specificity Neurokinin-1, and pharmacologically define 5-HT3, receptor antagonistremedy.


Methods:The study was Randomised, double-blind double-dummy, parallel- group, study, however phase 1 an ICH E14 QT trails as  200 mg netupitant + 0.5 mg palonosetron (NEPA200/0.5), 600 mg netupitant + 1.5 mg palonosetron (NEPA600/1.5, a supratherapeutic dose), and 400 mg moxifloxacin  400 mg moxifloxacin, Phase 2 As a cisplatin-situate  chemotherapy for solid tumours contrast three indiidual oral doses of NETU(100, 200,and 300 mg) +PALO 0.50mg with oral PALO 0.50mg, all given on day 1,for highly emetogenic chemotherapy, MEC was phase 3 study (anthracycline–cyclophosphamide) chemotherapy evaluated the efficacy and safety of a single oral dose of NEPA versus a single oral dose (0.50mg) of PALO. Oral Dexamethasone (DEX) on day1only (12 mgintheNEPAarmand20 mg in the PALO arm).


Conclusion:While all NEPA doses were profoundly successful and very much endured, while considering all endpoints and time intervals, NEPA300 was fixed-dose combination. It brought about predominant counteraction of CINV than PALO and in addition to DEX offers helpful guideline-based prophylaxis.This gives a chance to defeat obstructions restrict with guideline adherence and portray the NEPA is silver bullet for CINV therapy.

Keywords: Chemotherapy, Neurokinin-1 antagonist(Netupitant), 5-HT3 antagonist(Palanosetron), Chemotherapy trigger zone(CTZ), central and peripheral pathway of vomiting centre

Downloads

Download data is not yet available.

References

1. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J 2008; 14: 85–93. 2.
2. Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 2007; 61: 162–175.
3. NCCN. National Comprehensive Cancer Network: Antiemesis, Clinical Practice Guidelines in Oncology-v.1. 2010. www.nccn.org (4 October 2010, date last accesse.
4. Frame DG. Best practice management of CINV in oncology patients: I. physiology and treatment of CINV. Multiple neurotransmitters and receptors and the need for combination therapeutic approaches. J Support Oncol 2010; 8(1): 5–9.
5. Rojas C, Slusher BS. Pharmacological mechanism of 5-HT3 and tachykinin NK-1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 2012; 684: 1–7.
6. Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570–1577.
7. Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy randomized, comparative phase III trial. Lancet Oncol 2009; 10: 115–124.
8. Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17: 1441–1449
9. Stathis M, Pietra C, Rojas C et al. Inhibition of substance P-mediated responses in NG108–15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol 2012; 689: 25–30.
10. Grunberg S, Voisin D, Zufferli M et al. Oral palonosetron is as effective as intravenous palonosetron: a phase 3 dose ranging trial in patients receiving moderately emetogenic chemotherapy. Eur J Cancer 2007; 5 (Suppl 4): abstr 1143, p. 155.
11. Boccia R, Grunberg S, Franco-Gonzales E et al. Efficacy of oral palonosetron compared to intravenous palonosetron for prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial. Support Care Cancer 2013; 21: 1453–1460.
12. 10.Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 2009; 69:1853–1878.
13. 11. Grunberg SM, Warr D, Gralla RJ et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art. Support Care Cancer 2011; 19(Suppl1): S43–S47.
14. . Gralla R, Bosnjak S, Honsta A et al. A phase 3 study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting (CINV) over repeated cyclesof chemotherapy. Ann Oncol 2014; 25: 1333–1339.
Statistics
32 Views | 8 Downloads
Citatons
How to Cite
Pasula, S., G. Kothakoti, A. Alluri, G. R. Geetha Rekulapally, B. D. P. Beda Durga Prasad, and A. S. R. A. Srinivasa Rao. “COGNIZANCE ANALYSIS OF MAGICAL REMEDY COMBINATION OF NETUPITANT AND PALANOSETRON(NEPA) FOR CHEMOTHERAPY INDUCED NAUSEA AND VOMITING THERAPY”. International Journal of Pharmacognosy and Chemistry, June 2020, pp. 41-45, https://www.saapbooks.com/journals/index.php/ijpc/article/view/22.
Section
Review Article